gland pharma glp-1 capacity A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes drugs GLP-1 Drug Manufacturing: Expansion &

by 2030 could be on a weight loss drug, according to JP Morgan Research

Semaglutides trade-offs are cost, gastrointestinal side effects, contraindications including medullary thyroid carcinoma history, and the need for careful titration

It's the most important question you can ask about any formula - and it applies across the entire supplement category, not just to Trimology

Pharmaceutical companies have invested heavily in improving injection devices to enhance patient convenience and adherence

With decades of expertise in wellness, the brand is known for creating supplements that support overall health from within